PMID- 33830031
OWN - NLM
STAT- MEDLINE
DCOM- 20210702
LR  - 20210702
IS  - 2666-6367 (Electronic)
IS  - 2666-6367 (Linking)
VI  - 27
IP  - 2
DP  - 2021 Feb
TI  - Impact of Specific Antibody Level on Human Herpesvirus 6 Reactivation after 
      Allogeneic Stem Cell Transplantation.
PG  - 174.e1-174.e5
LID - S2666-6367(20)30019-1 [pii]
LID - 10.1016/j.jtct.2020.10.011 [doi]
AB  - The majority of adults are seropositive for human herpesvirus 6 (HHV-6). HHV-6 
      reactivation can occur after allogeneic hematopoietic stem cell transplantation 
      (HSCT) and lead to life-threatening central nervous system disorders. In this 
      prospective study, we evaluated the relationship between HHV-6 reactivation and 
      anti-HHV-6 IgG antibody levels in recipients of allogeneic HSCT. The HHV-6 viral 
      load in the plasma was quantitatively measured weekly after allogeneic HSCT by 
      real-time polymerase chain reaction. The level of anti-HHV-6 IgG antibody was 
      measured by enzyme-linked immunosorbent assay before and serially after 
      transplantation. In 28 of the 56 evaluated patients (50%), HHV-6 reactivation was 
      detected after transplantation. In a multivariate analysis, cord blood as the 
      stem cell source was the only significant factor associated with HHV-6 
      reactivation (odds ratio, 8.6; 95% confidence interval, 2.3 to 32.6; P < .01). 
      When evaluated in the recipients of cord blood transplantation (CBT), the 
      anti-HHV-6 antibody level before transplantation was significantly lower in the 
      patients with HHV-6 reactivation compared with those without (sample positivity 
      index: median, 2.04 [range, 0.95 to 5.98] versus 4.15 [range, 3.93 to 5.65]; P < 
      .05). The anti-HHV-6 antibody level was significantly decreased at 3 months 
      post-transplantation compared with before transplantation (P < .01). Such 
      differences were not observed in other stem cell sources. Our results demonstrate 
      that the low anti-HHV-6 antibody level before transplantation was associated with 
      the reactivation of HHV-6 after CBT, and that the anti-HHV-6 antibody level was 
      significantly decreased specifically after CBT. These results suggest that 
      HHV-6-specific humoral immunity plays a role in HHV-6 reactivation after CBT.
CI  - Copyright (c) 2020 The American Society for Transplantation and Cellular Therapy. 
      Published by Elsevier Inc. All rights reserved.
FAU - Nakayama, Hitomi
AU  - Nakayama H
AD  - Division of Hematology, Department of Medicine, Keio University School of 
      Medicine, Tokyo, Japan.
FAU - Yamazaki, Rie
AU  - Yamazaki R
AD  - Division of Hematology, Department of Medicine, Keio University School of 
      Medicine, Tokyo, Japan; Center for Transfusion Medicine and Cell 
      Therapy, Keio University School of Medicine, Tokyo, Japan. Electronic address: 
      r-yamazaki@keio.jp.
FAU - Kato, Jun
AU  - Kato J
AD  - Division of Hematology, Department of Medicine, Keio University School of 
      Medicine, Tokyo, Japan.
FAU - Koda, Yuya
AU  - Koda Y
AD  - Division of Hematology, Department of Medicine, Keio University School of 
      Medicine, Tokyo, Japan.
FAU - Sakurai, Masatoshi
AU  - Sakurai M
AD  - Division of Hematology, Department of Medicine, Keio University School of 
      Medicine, Tokyo, Japan.
FAU - Mori, Takehiko
AU  - Mori T
AD  - Division of Hematology, Department of Medicine, Keio University School of 
      Medicine, Tokyo, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201211
PL  - United States
TA  - Transplant Cell Ther
JT  - Transplantation and cellular therapy
JID - 101774629
SB  - IM
MH  - Adult
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects
MH  - *Herpesvirus 6, Human
MH  - Humans
MH  - Prospective Studies
MH  - *Roseolovirus Infections
MH  - Transplantation, Homologous
OTO - NOTNLM
OT  - Allogeneic hematopoietic stem cell transplantation
OT  - Enzyme-linked immunosorbent assay
OT  - Human herpesvirus 6
OT  - Humoral immunity
OT  - Reactivation
EDAT- 2021/04/09 06:00
MHDA- 2021/07/03 06:00
CRDT- 2021/04/08 12:26
PHST- 2020/08/21 00:00 [received]
PHST- 2020/10/10 00:00 [revised]
PHST- 2020/10/14 00:00 [accepted]
PHST- 2021/04/08 12:26 [entrez]
PHST- 2021/04/09 06:00 [pubmed]
PHST- 2021/07/03 06:00 [medline]
AID - S2666-6367(20)30019-1 [pii]
AID - 10.1016/j.jtct.2020.10.011 [doi]
PST - ppublish
SO  - Transplant Cell Ther. 2021 Feb;27(2):174.e1-174.e5. doi: 
      10.1016/j.jtct.2020.10.011. Epub 2020 Dec 11.